Skip to main content
SpringerLink
Log in

Method for indirect radiofluorination with [18F]FDG by biorthogonal reaction

  • Regular Article
  • Published:
The European Physical Journal Special Topics Aims and scope Submit manuscript

A Correction to this article was published on 03 July 2023

This article has been updated

Abstract

The [18F]-fluorodeoxyglucose ([18F]FDG) is a universal PET—radiopharmaceutical routinely applauded (oncology, cardiology and neurology) and produced by medical cyclotrons (18O(p,n)18F) in many clinics of Nuclear Medicine. Current trend in medicine is to become more personalized and new types of therapeutic and diagnostic radiopharmaceuticals are applied involving pre-targeting strategy. Using existing facilities and equipment in clinics for specific modification of approved radiopharmaceutical as [18F]FDG will provide unique toolbox in hands of physicians and will forward personalization of therapy in Nuclear Medicine. In the present study investigation over conjugation between [18F]FDG and aminooxy functionalized tetrazine by chemoselective oxime bond formation was done. Method for direct labeling of tetrazine derivative (clickable with trans cyclooctene moieties) with [18F]FDG used standard clinical laboratory settings was developed. The synthesis was carried out in a weakly acidic condition—pH 4–4.3; at 70 °C and in the presence of p-methoxyaniline as a catalyst. The progress of the reactions was monitored by radio-TLC, HPLC and to conform final formulation IR-ATR spectroscopy was used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data availability

No Data associated in the manuscript. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Change history

References

  1. Carberry, P., Lieberman, B.P., Ploessl, K., Choi, S.R., Haase, D.N., Kung, H.F. New F-18 prosthetic group via oxime coupling. Bioconjug Chem, 2011;22(4):642–53 https://pubmed.ncbi.nlm.nih.gov/21452846/

  2. Valdivia A.O., López J.L. ,Vargas-Rodríguez Y.M. y González O.C., Producción de radiofármacos para tomografía por emisión de positrones (PET) y su aplicación en el diagnóstico de diversas enfermedades, México, Universidad Nacional Autónoma de México, 2016, https://www.elsevier.es/es-revista-educacion-quimica-78-articulo-produccion-radiofarmacos-tomografia-por-emision-S0187893X16300076

  3. Ermet J., Naumaier B., The radiopharmaceutical chemistry of fluorine-18: nucleophilic fluorination, Radiopharmaceutical chemistry, Switzerland, Springer Nature Switzerland AG, 2019

  4. Kilbourn M.R., Fluorine-18 labeling of radiopharmaceuticals, Washington, DC: The National Academies Press, 1990 https://www.nap.edu/catalog/20467/fluorine-18-labeling-of-radiopharmaceuticals

  5. Z. Li, P.S. Conti, Radiopharmaceutical chemistry for positron emission tomography. Adv. Drug Deliv. Rev. 62, 1031–1051 (2010). https://doi.org/10.1016/j.addr.2010.09.007

    Article  Google Scholar 

  6. Schirrmacher R, Wängler B, Bailey J, Bernard-Gauthier V, Schirrmacher E, Wängler C. Small Prosthetic Groups in 18F-Radiochemistry: Useful Auxiliaries for the Design of 18F-PET Tracers. Semin Nucl Med. 2017; 47(5):474–492, https://www.sciencedirect.com/science/article/abs/pii/S0001299817300545?via%3Dihub

  7. F. Wuest, Ch. Hultsch, M. Berndt, R. Bergmann, Direct labeling of peptides with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG). Bioorg. Med. Chem. Lett. 19, 5426–5428 (2009). https://doi.org/10.1016/j.bmcl.2009.07.108

    Article  Google Scholar 

  8. Jacobson O., Chen X., PET designated fluoride-18 production and chemistry, Curr Top Med Chem.; 10(11): 1048–1059, 2010

  9. IAEA (International Atomic Energy Agency) TECDOC SERIES No1968, Production and quality control of fluorine 18-labeled radiopharmaceuticals, 2021, https://www-pub.iaea.org/MTCD/Publications/PDF/TE-1968web.pdf

  10. Maschauer S. and Prante O., Sweetening Pharmaceutical Radiochemistry by 18F-Fluoroglycosylation: A Short Review, BioMed Research International Volume 2014 https://www.hindawi.com/journals/bmri/2014/214748/

  11. Li. X.G., Haaparanta M., Solin O., Oxime formation for fluorine-18 labeling of peptides and proteins for positron emission tomography (PET) imaging: A review, Journal of Fluorine Chemistry 143 (2012) 49–56 https://www.sciencedirect.com/science/article/abs/pii/S0022113912002448

  12. Áliva-Rodríguez M. A., Sanchez H.A., Radiofármacos para PET, una nueva perspectiva de la medicina nuclear molecular en México, México, Unidad PET, Facultad de Medicina, Universidad Nacional Autónoma de México, 2010 https://www.medigraphic.com/pdfs/residente/rr-2010/rr103c.pdf

  13. Rodríguez-Sánchez A.M., Establecimiento de controles de calidad para 18F-FDG sintetizada por hidrólisis básica y evaluación de dosis de cristalino de POE de radiofarmacia PET con EPD, OSL y TLD, Argentina, Universidad Nacional de Cuyo, 2016 (tesis) http://ricabib.cab.cnea.gov.ar/579/1/1Rodriguez_S%C3%A1nchez.pdf

  14. Bouvet VR, Wuest F. Application of [18F]-FDG in radiolabeling reactions using microfluidic technology. Lab Chip. 2013;13(22):4290–4294. https://pubmed.ncbi.nlm.nih.gov/24056916/

  15. Keinänen O, Partelová D, Alanen O, Antopolsky M, Sarparanta M, Airaksinen AJ. Efficient cartridge purification for producing high molar activity [18F]fluoro-glycoconjugates via oxime formation. Nucl Med Biol. 2018;67:27–35. https://pubmed.ncbi.nlm.nih.gov/30380464/

  16. Ulrich S, Boturyn D, Marra A, Renaudet O, Dumy P. Oxime ligation: a chemoselective click-type reaction for accessing multifunctional biomolecular constructs. Chemistry. 2014;20(1):34–41. https://pubmed.ncbi.nlm.nih.gov/24302514/

  17. Namavari M, Padilla De Jesus O, Cheng Z, et al. Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol. 2008;10(4):177–181. https://pubmed.ncbi.nlm.nih.gov/18481153/

  18. Wester H.J., Schottelius M., Fluorine-18 Labeling of Peptides and Proteins, 2007;(62):79–111. https://doi.org/10.1007/978-3-540-49527-7_4

  19. Kölmel D.K. and Kool E.T., Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis, American Chemical society, 2017;117(15):10358–10376. https://doi.org/10.1021/acs.chemrev.7b00090

  20. Larsen D, Kietrys A.M.,  Clark S.A., Park H.Sh.,  Ekebergh A. and Kool E.T., Exceptionally rapid oxime and hydrazone formation promoted by catalytic amine buffers with low toxicity, Chemical science, 2018. https://pubs.rsc.org/en/content/articlelanding/2018/sc/c8sc01082j

  21. Wuest F., Berndt M., Bergmann R., Van den Hoff J. and Pietzsch J., Synthesis and Application of [18F]FDG-Maleimidehexyloxime ([18F]FDG-MHO): A [18F]FDG-Based Prosthetic Group for the Chemoselective 18F-Labeling of Peptides and Proteins, Bioconjugate Chemistry, 2008, 19, 1202–1210. https://doi.org/10.1021/bc8000112

  22. Rashidian M., Keliher E.J., Dougan M. et al., Use of 18F-2-Fluorodeoxyglucose to label antibody fragments for immuno-positron emission tomography of pancreatic cancer, American Chemical society, 2015 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778250/pdf/oc5b00121.pdf

  23. Kettenbach K, Schieferstein H, Ross TL. 18F-labeling using click cycloadditions. Biomed Res Int. 2014; 2014: 361329. https://pubmed.ncbi.nlm.nih.gov/25003110/

  24. Simeonova G.,Todorov B., Lyubomirova V., Modification of 18F-fluorodesoxy-glucose (18F-FDG) radiopharmaceutical by oxime conjugation, 2021, RAP CONFERENCE PROCEEDINGS, VOL. 6, PP. 11–15 https://www.rap-proceedings.org/papers/RapProc.2021.03.pdf

Download references

Acknowledgements

The authors are grateful for the support provided by the Research Fund at the Ministry of Education and Science (contract № KP-06-N29/4).

Author information

Authors and Affiliations

  1. UMHAT “St. Marina”, Cl. in Nuclear Medicine, 1 Hristo Smirnenski Blvd., Varna, Bulgaria

    Gergana Simeonova

  2. Department of Analytical Chemistry, Faculty of Chemistry and Pharmacy, 1 James Boucher Str., Sofia, Bulgaria

    Gergana Simeonova, Boyan Todorov & Valentina Lyubomirova

Authors
  1. Gergana Simeonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boyan Todorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Lyubomirova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gergana Simeonova.

Ethics declarations

Conflict of interest

The authors declared that there is no conflict of interest with respect to this research.

Additional information

The original online version of this article was revised: The captions of Fig. 6 and Fig. 7 had mistakes. The captions have now been corrected.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simeonova, G., Todorov, B. & Lyubomirova, V. Method for indirect radiofluorination with [18F]FDG by biorthogonal reaction. Eur. Phys. J. Spec. Top. 232, 1555–1562 (2023). https://doi.org/10.1140/epjs/s11734-023-00885-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1140/epjs/s11734-023-00885-7

Search

Navigation